Chemistry:Dipraglurant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C16H12FN3 |
| Molar mass | 265.291 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]
See also
References
- ↑ 1.0 1.1 Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. 29 July 2013. pp. 255–. ISBN 978-1-84973-617-6. https://books.google.com/books?id=g3_8KlQvenAC&pg=PA255.
- ↑ Annual Reports in Medicinal Chemistry. Academic Press. 2012. pp. 83–. ISBN 978-0-12-396492-2. https://books.google.com/books?id=xpe9Mk50BGsC&pg=PA83.
- ↑ Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. 8 October 2014. pp. 323–. ISBN 978-1-4471-6503-3. https://books.google.com/books?id=ME69BAAAQBAJ&pg=PA323.
- ↑ "Dipraglurant-ER for dystonia". Addex Therapeutics. http://www.addextherapeutics.com/rd/pipeline/dipra-er/.
External links
- Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics
- Dipraglurant-ER for dystonia - Addex Therapeutics
 |  |
